Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.89 |
| ▸ | LTA4H | P09960 | 3/20 | 0.55 |
| ▸ | HTR6 | P50406 | 4/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167189 | 1.00 | POLB (0.89) | POLBLTA4HHTR6GBA1 | |
| SCHEMBL1860551 | 1.00 | POLB (0.89) | POLBLTA4HHTR6GBA1 | |
| SCHEMBL8872309 | 0.94 | POLB (1.00) | POLBLTA4HGBA1 | |
| SCHEMBL8872248 | 0.94 | POLB (1.00) | POLBLTA4HGBA1 | |
| SCHEMBL2707343 | 0.94 | POLB (1.00) | POLBLTA4HGBA1 | |
| SCHEMBL23459143 | 0.92 | POLB (0.96) | POLBLTA4HGBA1 | |
| Hydrochloric Acid SCHEMBL7247583 | 0.92 | POLB (0.96) | POLBLTA4HHTR6 | |
| SCHEMBL11472596 | 0.92 | POLB (0.96) | POLBLTA4HGBA1 | |
| SCHEMBL11375632 | 0.89 | POLB (0.72) | POLBLTA4HHTR6 | |
| SCHEMBL17542062 | 0.85 | POLB (0.71) | POLBGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106914234-B | 'Almond-shaped' Mn2O3Preparation method of/C particles | 广西大学 | 2020-11-06 | — | — | CN | claimed |
| CN-106887606-B | Peach-shaped Mn2O3preparation method of/C particles | 广西大学 | 2019-12-13 | — | — | CN | claimed |
| EP-2791139-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | Dr Reddys Laboratories Ltd (IN) | 2017-11-08 | — | — | EP | claimed |
| EP-2791139-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | Dr. Reddy's Laboratories Ltd. (IN) | 2014-10-22 | — | — | EP | claimed |
| WO-2013088257-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-06-20 | — | — | WO | claimed |
| CN-101784552-A | Derivatives of 6-cycloamino-3- (pyridazin-4-yl) imidazo [1,2-b ] pyridazine, preparation thereof and therapeutic use thereof | SANOFI AVENTIS | 2010-07-21 | — | — | CN | claimed |
| CN-101765602-A | Derivatives of 6-cycloamino-3- (pyridin-4-yl) imidazo [1,2-b ] pyridazine, preparation thereof and therapeutic use thereof | SANOFI AVENTIS | 2010-06-30 | — | — | CN | claimed |
| JP-3151358-A | — | — | None | — | — | JP | disclosed |
| EP-4069366-B1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-5135944-A | Bis(benzylpyrrolidine) derivatives useful for treating congestive heart failure and acute renal failure | SYNTEX (U.S.A.) INC. (US) | 1992-08-04 | — | — | US | disclosed |
| US-5100912-A | Hypotensive agents, treatment of congestive heart failure | SYNTEX (U.S.A.) INC. (US) | 1992-03-31 | — | — | US | disclosed |
| US-5064944-A | Gas Chromatography | ADVANCED SEPARATION TECHNOLOGIES INC. (US) | 1991-11-12 | — | — | US | disclosed |
| JP-H03151358-A | BENZYLPYRROLIDINE DERIVATIVE AS DOPAMINE AGONIST | SYNTEX USA INC | 1991-06-27 | — | — | JP | disclosed |
| EP-0426075-A1 | Benzylpyrrolidine derivatives as dopamine agonists | SYNTEX (U.S.A.) INC. (US) | 1991-05-08 | — | — | EP | disclosed |
| US-4279918-A | ANTIDEPRESSANTS, STIMULANTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK G.M.B.H. (DE) | 1981-07-21 | — | — | US | disclosed |
| US-4279918-A | ANTIDEPRESSANTS, STIMULANTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK G.M.B.H. (DE) | 1981-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | POLB 1879/4885LTA4H 4425/4885HTR6 3133/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | POLB 1879/4885LTA4H 4425/4885HTR6 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.